61948-86-5

Usage

Uses

Used in Pharmaceutical Industry:
2,4(1H,3H)-Quinazolinedione, 5-methoxyis used as a potential therapeutic agent for the treatment of various diseases and conditions, such as cancer and neurodegenerative disorders. Its unique chemical structure and properties make it a promising candidate for drug development, as it may exhibit specific biological activities and interactions with target molecules in these diseases.
Used in Chemical Synthesis:
2,4(1H,3H)-Quinazolinedione, 5-methoxyis used as a building block in the synthesis of other organic compounds. Its versatile chemical structure allows for further functionalization and modification, enabling the development of new compounds with potential applications in various fields, such as pharmaceuticals, materials science, and agrochemicals.
Used in Research and Development:
2,4(1H,3H)-Quinazolinedione, 5-methoxyis used as a subject of research to explore its potential applications and properties. Studies on 2,4(1H,3H)-Quinazolinedione, 5-methoxy- can provide valuable insights into its biological activities, interactions with target molecules, and potential use in various fields, contributing to the advancement of scientific knowledge and the development of new technologies and applications.

Upstream product

• 1591-38-4 2-amino-6-methoxybenzamide 
• 53600-33-2 6-methoxyanthranilic acid 
• 57-13-6 urea 
• 6705-03-9 2-Amino-5-methoxybenzoic acid 
• 1591-37-3 2-amino-6-methoxybenzonitrile 
• 38469-85-1 2-methoxy-6-nitrobenzonitrile 
• 857977-64-1 2-methoxy-6-ureido-benzoic acid amide 

Downstream Products

• 61948-59-2 2,4-dichloro-5-methoxy-quinazoline 
• 105763-77-7 2,4-dichloro-6-methoxy-quinazoline 

Relevant academic research and scientific papers

Design, synthesis and biological evaluation of 2-aminoquinazolin-4(3H)-one derivatives as potential SARS-CoV-2 and MERS-CoV treatments

Despite the rising threat of fatal coronaviruses, there are no general proven effective antivirals to treat them. 2-Aminoquinazolin-4(3H)-one derivatives were newly designed, synthesized, and investigated to show the inhibitory effects on SARS-CoV-2 and MERS-CoV. Among the synthesized derivatives, 7-chloro-2-((3,5-dichlorophenyl)amino)quinazolin-4(3H)-one (9g) and 2-((3,5-dichlorophenyl)amino)-5-hydroxyquinazolin-4 (3H)-one (11e) showed the most potent anti-SARS-CoV-2 activities (IC50 50 50 > 25 μM). In addition, both compounds showed acceptable results in metabolic stabilities, hERG binding affinities, CYP inhibitions, and preliminary PK studies.

Antileishmanial activity of a series of N2, N 4-disubstituted quinazoline-2,4-diamines

A series of N2,N4-disubstituted quinazoline-2,4- diamines has been synthesized and tested against Leishmania donovani and L. amazonensis intracellular amastigotes. A structure-activity and structure-property relationship study was conducted in part using the Topliss operational scheme to identify new lead compounds. This study led to the identification of quinazolines with EC50 values in the single digit micromolar or high nanomolar range in addition to favorable physicochemical properties. Quinazoline 23 also displayed efficacy in a murine model of visceral leishmaniasis, reducing liver parasitemia by 37% when given by the intraperitoneal route at 15 mg kg-1 day-1 for 5 consecutive days. Their antileishmanial efficacy, ease of synthesis, and favorable physicochemical properties make the N2,N 4-disubstituted quinazoline-2,4-diamine compound series a suitable platform for future development of antileishmanial agents.

FRET enabled real time detection of RNA-small molecule binding

A robust analysis and discovery platform for antibiotics targeting the bacterial rRNA A-site has been developed by incorporating a new emissive U surrogate into the RNA and labeling the aminoglycosides with an appropriate fluorescence acceptor. Specifical

ACYCLIC IKUR INHIBITORS

A compound of formula I wherein R1, R2, R3, R4 and R5 are described herein.

Tricyclic dicarbonyl derivatives

Compounds of general formula (Ia), (Ib) and (II), wherein R1 and R2 each independently signify hydrogen, lower alkyl, lower alkoxy, nitro, trifluoromethyl, amino, halogen, cyano or R3 R4 NS(O)2 -- and R3 and R4 signify lower alkyl, and R2 can additionally signify morpholino or thiomorpholino, a 5- or 6-membered heterocycle with 1-3N atoms optionally substituted by lower alkyl, hydroxy, amino or the group --CH2 NHCH3, a bicyclic heterocycle with 1-3N atoms or a group --NR5 R6 or --OR5 in which R5 and R6 can be the same or different and signify hydrogen, lower alkyl, hydroxy-lower alkyl, lower alkoxy-lower alkyl, amino-lower alkyl or lower alkylamino-lower alkyl, and X in formula (II) signifies --CH=CH--, --CH=N--, --NH--, --CO-- or --O--, as well as pharmaceutically usable salts of compounds of general formula (Ia), (Ib) and (II). They can be used for the treatment or prevention of illnesses, especially for the treatment or prevention of ischemia, hypoglycaemia, hypoxia, cerebral vascular spasms, spasticity, trauma, hemorrhagia, infection (viral, bacterial, amoebic, prional), epileptic seizures, autoimmune diseases, withdrawal symptoms, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's disease, intoxications, olivoponto-cerebellar atrophy, spinal cord injuries, schizophrenia, depressions, anxiety states, dependence, pains,autism and mental retardation.